These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25312040)

  • 1. Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia.
    Bastard M; Sanchez-Padilla E; Hewison C; Hayrapetyan A; Khurkhumal S; Varaine F; Bonnet M
    J Infect Dis; 2015 May; 211(10):1607-15. PubMed ID: 25312040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study.
    Sanchez-Padilla E; Marquer C; Kalon S; Qayyum S; Hayrapetyan A; Varaine F; Bastard M; Bonnet M
    Int J Tuberc Lung Dis; 2014 Feb; 18(2):160-7. PubMed ID: 24429307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.
    Kibret KT; Moges Y; Memiah P; Biadgilign S
    Infect Dis Poverty; 2017 Jan; 6(1):7. PubMed ID: 28093078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study.
    Javaid A; Ullah I; Masud H; Basit A; Ahmad W; Butt ZA; Qasim M
    Clin Microbiol Infect; 2018 Jun; 24(6):612-617. PubMed ID: 28970158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes.
    Podewils LJ; Gler MT; Quelapio MI; Chen MP
    PLoS One; 2013; 8(7):e70064. PubMed ID: 23922904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.
    Mitnick C; Bayona J; Palacios E; Shin S; Furin J; Alcántara F; Sánchez E; Sarria M; Becerra M; Fawzi MC; Kapiga S; Neuberg D; Maguire JH; Kim JY; Farmer P
    N Engl J Med; 2003 Jan; 348(2):119-28. PubMed ID: 12519922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China.
    Wei XL; Yin J; Zou GY; Zhang ZT; Walley J; Harwell J; Li HT; Sun Q; Li RZ; Wang LX; Zhang XL
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):413-9. PubMed ID: 25859996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic.
    Kim HJ; Hong YP; Kim SJ; Lew WJ; Lee EG
    Int J Tuberc Lung Dis; 2001 Dec; 5(12):1129-36. PubMed ID: 11769771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
    Park SK; Lee WC; Lee DH; Mitnick CD; Han L; Seung KJ
    Int J Tuberc Lung Dis; 2004 Mar; 8(3):361-8. PubMed ID: 15139476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription patterns and treatment outcomes of MDR-TB patients treated within and outside the National Tuberculosis Programme in Pham Ngoc Thach hospital, Viet Nam.
    Hoa NB; Khanh PH; Chinh NV; Hennig CM
    Trop Med Int Health; 2014 Sep; 19(9):1076-81. PubMed ID: 24995611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia.
    Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Nikiforov M; Yedilbayev A; Mukherjee JS; Furin JJ; Barry DJ; Farmer PE; Rich ML; Keshavjee S
    Int J Tuberc Lung Dis; 2006 Apr; 10(4):402-8. PubMed ID: 16602404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.
    Aibana O; Bachmaha M; Krasiuk V; Rybak N; Flanigan TP; Petrenko V; Murray MB
    BMC Infect Dis; 2017 Feb; 17(1):129. PubMed ID: 28173763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment interruptions and duration associated with default among new patients with tuberculosis in six regions of Russia.
    Jakubowiak W; Bogorodskaya E; Borisov S; Danilova I; Kourbatova E
    Int J Infect Dis; 2009 May; 13(3):362-8. PubMed ID: 19008141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors and mortality associated with treatment default in pulmonary tuberculosis.
    Kliiman K; Altraja A
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):454-63. PubMed ID: 20202304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors of treatment interruptions among drug-sensitive and drug-resistant pulmonary tuberculosis patients - A study from South Delhi, New Delhi, India.
    Kumar L; Kumar S; Vohra V; Mohan K; Khayyam KU
    Indian J Tuberc; 2024; 71 Suppl 1():S72-S76. PubMed ID: 39067959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent treatment interruption and its effect on multidrug resistant tuberculosis treatment outcome in Ethiopia.
    Tola HH; Holakouie-Naieni K; Mansournia MA; Yaseri M; Tesfaye E; Mahamed Z; Sisay MM
    Sci Rep; 2019 Dec; 9(1):20030. PubMed ID: 31882784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance.
    Ahmad N; Javaid A; Basit A; Afridi AK; Khan MA; Ahmad I; Sulaiman SA; Khan AH
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1109-14, i-ii. PubMed ID: 26260834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
    Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
    Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.